Oruka Therapeutics Statistics
Total Valuation
ORKA has a market cap or net worth of $5.60 billion. The enterprise value is $4.47 billion.
| Market Cap | 5.60B |
| Enterprise Value | 4.47B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ORKA has 66.21 million shares outstanding. The number of shares has increased by 49.96% in one year.
| Current Share Class | 66.21M |
| Shares Outstanding | 66.21M |
| Shares Change (YoY) | +49.96% |
| Shares Change (QoQ) | +13.96% |
| Owned by Insiders (%) | 2.21% |
| Owned by Institutions (%) | 101.23% |
| Float | 56.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.64 |
| P/TBV Ratio | 5.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.51, with a Debt / Equity ratio of 0.00.
| Current Ratio | 38.51 |
| Quick Ratio | 38.03 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.23% and return on invested capital (ROIC) is -13.25%.
| Return on Equity (ROE) | -18.23% |
| Return on Assets (ROA) | -12.95% |
| Return on Invested Capital (ROIC) | -13.25% |
| Return on Capital Employed (ROCE) | -13.89% |
| Weighted Average Cost of Capital (WACC) | 3.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +353.92% in the last 52 weeks. The beta is -0.21, so ORKA's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | +353.92% |
| 50-Day Moving Average | 95.76 |
| 200-Day Moving Average | 63.92 |
| Relative Strength Index (RSI) | 38.28 |
| Average Volume (20 Days) | 994,982 |
Short Selling Information
The latest short interest is 7.62 million, so 11.51% of the outstanding shares have been sold short.
| Short Interest | 7.62M |
| Short Previous Month | 7.79M |
| Short % of Shares Out | 11.51% |
| Short % of Float | 13.40% |
| Short Ratio (days to cover) | 9.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -155.08M |
| Pretax Income | -132.89M |
| Net Income | -109.69M |
| EBITDA | -154.94M |
| EBIT | -155.08M |
| Earnings Per Share (EPS) | -$2.02 |
Balance Sheet
The company has $873.56 million in cash and $2.55 million in debt, with a net cash position of $1.12 billion or $16.96 per share.
| Cash & Cash Equivalents | 873.56M |
| Total Debt | 2.55M |
| Net Cash | 1.12B |
| Net Cash Per Share | $16.96 |
| Equity (Book Value) | 1.11B |
| Book Value Per Share | 18.20 |
| Working Capital | 861.59M |
Cash Flow
In the last 12 months, operating cash flow was -$100.92 million and capital expenditures -$235,000, giving a free cash flow of -$101.15 million.
| Operating Cash Flow | -100.92M |
| Capital Expenditures | -235,000 |
| Depreciation & Amortization | 134,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -101.15M |
| FCF Per Share | -$1.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORKA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.96% |
| Shareholder Yield | -49.96% |
| Earnings Yield | -1.96% |
| FCF Yield | -1.81% |
Analyst Forecast
The average price target for ORKA is $155.00, which is 83.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $155.00 |
| Price Target Difference | 83.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 3, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Sep 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |